Loading
30 evidence-based guides on how common medications affect the kidneys — what the trials show, how dosing changes with kidney function, and what to watch for. Every guide cites its sources.
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and obesity. The FLOW trial (NEJM 2024) showed it significantly slows kidney disease progression in people with type 2 diabetes and CKD — one of the most important kidney-protective findings of the decade.
Read the guideSGLT2 inhibitors — originally diabetes drugs — are now a cornerstone of kidney disease treatment. DAPA-CKD and EMPA-KIDNEY trials proved they slow kidney failure by 30-40% in CKD with and without diabetes, and reduce heart failure hospitalizations.
Read the guideDapagliflozin is the first SGLT2 inhibitor proven to protect kidneys in CKD with and without diabetes (DAPA-CKD trial, NEJM 2020) — a 39% reduction in kidney failure risk. It also treats heart failure and is taken as one tablet a day.
Read the guideEmpagliflozin is an SGLT2 inhibitor approved for CKD with albuminuria (eGFR ≥20) and heart failure. The EMPA-KIDNEY trial (NEJM 2023) — the largest CKD trial ever — showed a 28% reduction in kidney disease progression.
Read the guideFinerenone is a new-generation mineralocorticoid receptor antagonist for diabetic kidney disease. The FIDELIO-DKD trial (NEJM 2020) showed it cuts kidney failure risk by 18% on top of ACEi/ARB — without the potassium and hormone side effects of older spironolactone.
Read the guideMetformin is the first-line diabetes drug — and it is safe in kidney disease down to eGFR 30, per the 2016 FDA label revision. Below 30 it's stopped because of lactic acidosis risk. The old 'never in kidney disease' fear is outdated.
Read the guideApixaban is the preferred blood thinner for atrial fibrillation in kidney disease — it has the most flexible renal dosing of the NOACs and is even label-approved for use on dialysis (5 mg BID).
Read the guideRivaroxaban is a once-daily NOAC. In kidney disease, dosing depends on CrCl: 20 mg daily above CrCl 50, 15 mg daily at CrCl 15-49, and it should be avoided below CrCl 15. Rivaroxaban also protects against atherosclerotic events in CKD (COMPASS trial).
Read the guideDabigatran is the most kidney-dependent of the NOACs (~80% renally cleared). Dosing is tightly tied to CrCl: 150 mg BID above 50, 75 mg BID at 15-30 (US label), and it's avoided below CrCl 15 and on dialysis.
Read the guideNSAIDs are the most common preventable cause of kidney injury — they reduce kidney blood flow, raise blood pressure, and blunt the effect of blood pressure and kidney-protective medications. In CKD they should be largely avoided.
Read the guideColchicine is the standard treatment for gout flares — but it is eliminated by the kidneys and has a narrow safety window. In CKD, doses must drop sharply: down to 0.3 mg twice weekly on dialysis. Getting this wrong causes severe myopathy and marrow toxicity.
Read the guideAllopurinol is the standard urate-lowering drug for gout — and it's safe in CKD when started low and titrated slowly. Its metabolite oxypurinol accumulates with kidney disease, and dosing adjustments prevent both toxicity and the rare but serious hypersensitivity reaction.
Read the guideGabapentin is widely used for nerve pain, restless legs, and dialysis-related cramps — but it is cleared entirely by the kidneys. Unadjusted dosing in CKD causes severe sedation, dizziness, and falls, especially in dialysis patients, who need dosing after each dialysis session.
Read the guideFebuxostat is the main alternative to allopurinol for lowering uric acid in gout — and it does not require the same slow renal titration, since it's mostly metabolized by the liver. Its role in CKD is significant: gout is common and NSAIDs are often off-limits.
Read the guidePregabalin is used for nerve pain, fibromyalgia, and restless legs — and like gabapentin, it is cleared entirely by the kidneys. Unadjusted dosing in CKD causes severe sedation, dizziness, and falls; the label provides CrCl-based dose tables.
Read the guideDigoxin is a heart-failure and atrial-fibrillation drug with a narrow therapeutic window — and it is eliminated largely by the kidneys. CKD patients need smaller doses and careful monitoring, because toxicity (nausea, visual changes, arrhythmias) develops at lower doses when clearance falls.
Read the guideLithium is the gold-standard mood stabilizer — and one of the few drugs that can directly damage the kidneys. Chronic use causes nephrogenic diabetes insipidus (excessive thirst/urination) and, in some, slowly progressive CKD. Careful monitoring protects both the mood stability and the kidneys.
Read the guideVancomycin is a workhorse IV antibiotic for serious infections — and it's both cleared by and toxic to the kidneys. In CKD and dialysis, dosing is level-guided and AKI risk is real. The mantra: right dose, right interval, right monitoring.
Read the guideSpironolactone helps heart failure and resistant hypertension — and its biggest kidney-related risk is hyperkalemia. In CKD, it's used carefully with potassium monitoring; the modern alternative finerenone offers kidney protection with a lower potassium risk.
Read the guideParicalcitol is an active vitamin D analog used in CKD-MBD to control secondary hyperparathyroidism — it suppresses PTH with less calcium and phosphorus rise than calcitriol. For dialysis patients with uncontrolled PTH, it's a standard part of bone-mineral management.
Read the guideCinacalcet lowers PTH directly by sensitizing the calcium-sensing receptor — used when secondary hyperparathyroidism persists despite vitamin D and binders. It also treats hypercalcemia in parathyroid carcinoma. In dialysis, it's the standard agent for severe uncontrolled PTH.
Read the guideSevelamer is a non-calcium phosphate binder — the modern standard for controlling phosphorus in dialysis and advanced CKD. Unlike calcium-based binders, it doesn't add to the calcium load, which matters for vascular calcification risk.
Read the guideStatins lower LDL cholesterol and cardiovascular risk — the #1 killer in CKD patients. They're safe in kidney disease, though doses of some statins (simvastatin, rosuvastatin) are capped at low eGFR. Statins do NOT slow CKD progression, but the heart protection is essential.
Read the guideInsulin requirements FALL as kidney function declines — the kidney clears insulin, so CKD prolongs its action. Insulin doses often need reduction in advanced CKD and dialysis, with hypoglycemia the main danger. For diabetic kidney disease, insulin is the reliable fallback when oral agents are limited.
Read the guideEplerenone is a selective aldosterone blocker for heart failure after MI — with less hormonal side effects than spironolactone. Like all MR antagonists, its kidney-related risk is hyperkalemia, requiring potassium monitoring in CKD.
Read the guideTacrolimus is the backbone immunosuppressant after kidney transplant — it quiets the T-cells that would attack the new kidney, and its blood levels are tuned like a dose dial. It is also used in selected autoimmune kidney diseases (lupus nephritis, membranous nephropathy) as a steroid-sparing agent.
Read the guideMycophenolate is the standard second immunosuppressant in kidney transplant (paired with tacrolimus) and a key treatment in lupus nephritis and other glomerular diseases. It blocks the immune cells that would attack the graft or drive autoimmune kidney damage.
Read the guideCyclosporine is the original calcineurin inhibitor — the drug that made modern transplantation possible (Nobel Prize in Medicine, 1990). It is still used in kidney transplant and as a steroid-sparing agent in nephrotic syndrome, though tacrolimus has largely replaced it as first-line.
Read the guideEverolimus is an mTOR inhibitor used in kidney transplant to 'spare' the kidneys: it suppresses immune-cell growth without the direct kidney toxicity of calcineurin inhibitors, so regimens use it (often with reduced tacrolimus) to protect long-term graft function.
Read the guidePrednisone is the oldest and most versatile drug in kidney care — high doses stop kidney inflammation in glomerular disease and rejection; low doses maintain transplant immunosuppression. Its side effects (glucose, bone, mood, weight) are the management challenge.
Read the guideAdvertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.